A Study of KC1036 in Adolescents With Advanced Ewing Sarcoma

Summary

This open-label, single-arm clinical trial is to evaluate the safety and effectiveness of KC1036 in treating adolescents aged 12 and above with advanced Ewing sarcoma. Participants will take KC1036 once daily, with each treatment cycle lasting 4 weeks.

Timeline

Start

2024-09-27

Primary completion

2027-04-01

Completion

2028-04-01

Drugs

Indications